Uncategorized

White House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO says 

Published

1 day ago

on

Biotechs with single products in the market are likely on edge about how President Donald Trump’s pharma tariffs and “most favored nation” pricing will play out, Rhythm Pharmaceuticals CEO David Meeker told Endpoints News in …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version